Home Press Releases Rare Disease Genetic Testing Market Size Worth $1.8 Billion by 2027 | CAGR: 10.6%

Rare Disease Genetic Testing Market Size Worth $1.8 Billion by 2027 | CAGR: 10.6%

The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027 according to a new study by Polaris Market Research. The reportRare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Ailments, Endocrine & Metabolism Disorders, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disorders, Others); By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020 – 2027gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player’s in cost-effective treatments are the key factors responsible for market growth. Moreover, government-sponsored schemes are also expected to positively impact the market. In February 2020, the government of India announced financial assistance of INR 15 lacs to the patients suffering from uncommon ailments under the Rashtriya Arogaya Nidhi scheme for a one-time treatment.

 

The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region. In terms of disease type, the market is segmented into neurological disorders, immunological disorders, hematology illnesses, endocrine & metabolism ailments, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology illnesses, and others.

 

Based on technology, the rare disease genetic testing industry is further bifurcated into next-generation sequencing, array technology, PCR-based testing, FISH, sanger sequencing, and karyotyping. Based on specialty, the rare disease genetic testing industry is further bifurcated into molecular, chromosomal, and biochemical genomic tests. Based on end-use, the rare disease genomic testing industry is further bifurcated into research laboratories & CROs, hospitals & clinics, and diagnostic laboratories.

 

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the following link: https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/request-for-sample

 

Segment Highlights

  • Neurological ailments accounted for the largest revenue share in 2019 on account of the increasing prevalence of neurologic disorders across the globe and presence of numerous testing techniques
  • Based on technology, the next generation sequencing segment is projected to constitute almost half of the market in 2027. The usage of the technology in whole genome sequencing is the key factor responsible for its segment’s growth.
  • Molecular tests are expected to account for the highest revenue share by the end of 2027. The availability of advanced technologies and ability to test ultra-rare disorders is expected to drive market growth.
  • Research laboratories & CROs accounted for the largest revenue share in 2019 owing to the increasing number of tests and growing occurrence of rare disorders across the developed economies

 

List of Key Players

  • Strand Life Sciences
  • Myriad Genetics
  • Quest Diagnostics Inc.
  • Centogene N.V.
  • Invitae Corporation
  • Baylor Genetics
  • Ambry Genetics
  • Macrogen, Inc.
  • Opko Health, Inc.
  • Color Genomics, Inc.
  • Health Network Laboratories
  • Preventiongenetics, Progenity, Inc.
  • Fulgent Genetics Inc.
  • Others

 

Polaris Market Research has segmented the rare disease genetic testing market report on the basis of disease type, technology, specialty, end-use, and region

Rare Disease Genetic Testing, Disease Type Outlook (Revenue – USD Million, 2016 – 2027)

  • Neurological Disorders
  • Immunological Disorders
  • Hematology Ailments
  • Endocrine & Metabolism Disorders
  • Cancer
  • Musculoskeletal Disorders
  • Cardiovascular Disorders
  • Dermatology Disorders
  • Others

Rare Disease Genetic Testing, Technology Outlook (Revenue – USD Million, 2016 – 2027)

  • Next Generation Sequencing
    • Whole Exome Sequencing
    • Whole Genome Sequencing
  • Array Technology
  • PCR-based Testing
  • FISH
  • Sanger Sequencing
  • Karyotyping

Rare Disease Genetic Testing, Specialty Outlook (Revenue – USD Million, 2016 – 2027)

  • Molecular Genetic Tests
  • Chromosomal Genetic Tests
  • Biochemical Genetic Tests

Rare Disease Genetic Testing, Technology Outlook (Revenue – USD Million, 2016 – 2027)

  • Research Laboratories & CROs
  • Hospitals & Clinics
  • Diagnostic Laboratories

Rare Disease Genetic Testing, Regional Outlook (Revenue – USD Million, 2016 – 2027)

  • North America
    • U.S.
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Netherlands
    • Austria
  • Asia Pacific
    • China
    • India
    • Japan
    • Malaysia
    • South Korea
    • Indonesia
  • Central & South America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

License and Pricing

Buy Now

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing

Request For Customization

Please specify your research requirement and get customized report


Regional AnalysisSegmentation AnalysisIndustry OutlookCompetitive Analysis
By using this form you agree with the storage and handling of your data by this website.

Speak to Analyst

By using this form you agree with the storage and handling of your data by this website.